ANIK Earnings & Financial Statements
Anika Therapeutics, Inc.
$19.58
+$0.45(+2.38%)
49
Overall
40
Value
60
Tech
47
Quality
Market Cap
$255.88M
Volume
75.52K
52W Range
$8.67 - $22.88
Target Price
$23.00
ANIK earnings and financial statements: Anika Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ANIK Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $112.82M | $119.91M | $120.79M | $156.24M | $147.79M |
| Cost of revenue | $49.01M | $43.91M | $38.26M | $62.66M | $64.85M |
| Operating income | -$11.05M | -$5.10M | $844.0K | -$19.40M | $2.62M |
| EBITDA | -$4.52M | -$43.62M | $9.51M | -$2.41M | -$4.16M |
| Net income | -$10.88M | -$56.38M | -$82.67M | -$14.86M | $4.13M |
| EPS (diluted) | $-0.76 | $-3.83 | $-5.64 | $-1.02 | $0.28 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $190.27M | $202.74M | $270.63M | $349.13M | $347.54M |
| Total liabilities | $46.80M | $48.75M | $58.37M | $63.56M | $60.45M |
| Shareholders’ equity | $143.47M | $153.99M | $212.26M | $285.56M | $287.08M |
| Cash and equivalents | $57.48M | $55.63M | $68.74M | $86.33M | $94.39M |
| Long-term debt | $24.20M | $24.01M | $25.91M | $28.82M | $19.24M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $11.19M | $5.40M | -$1.79M | $4.41M | $8.40M |
| Capital expenditure | -$6.23M | -$8.33M | -$5.43M | -$7.49M | -$5.14M |
| Free cash flow | $4.36M | -$2.93M | -$7.21M | -$3.08M | $3.25M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ANIK | $19.58 | +2.4% | 75.52K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Anika Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW